Other content in this Stream
From enabling the manufacturing of biopharmaceuticals to developing its own drug pipeline.
Prometic to initiate PBI-4050 pivotal phase 3 clinical trial in Alström Syndrome
Prometic provides corporate update
Prometic closes its extension of debt maturities to 2024
• Maturity Dates of the Line of Credit and Long-Term (OID) Loans extended to September 2024 • One of a number of measures underway to extend cash runway • Significant reduction in R&D costs of up ...
Annual Information Form 2017
Prometic Annual Information Form 2017
Quarterly Report Q2 2018
Quarterly Report Q1 2018
Prometic reports its 2018 first quarter highlights and financial results
Corporate Governance and Nominating Committee Charter 2017
Audit, Risk and Finance Committee Charter 2017
Chairman Mandate 2018
Code of Ethics and Business Conduct 2017
Full detailed breakdown of Prometics Code of Ethics and Business Conduct for 2017 including details on regulatory compliance.
Virtual Tour of Prometic Life Science's Manufacturing Process
Plasminogen Replacement Therapy for Congenital Plasminogen Deficiency
At Prometic Life Sciences we are committed to addressing unmet medical needs in rare diseases such as Congenital Plasminogen Deficiency (PLGD).
Joe Parker, MD: PBI-4050 Demonstrates Promising Efficacy Results for IPF Treatment